Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

LATE-BREAKING ABSTRACTS

LATE-BREAKING ABSTRACTS Company, Genentech. G. Consultant; Eli Lilly and Company, Genentech. LATE-BREAKING PLENARY D.R. Spigel: None. R.C. Hermann: B. Independent Contractor; Eli Lilly and Company. J. Liu: A. Employee; Eli Lilly and Company. K. Stock; Eli Lilly and Company. S.C. Guba: A. Employee; Eli Lilly and Company. K. LBPL1 Stock; Eli Lilly and Company. P. Bonomi: E. Research Grant; Eli Lilly A Randomized, Open-label, Phase 3, Superiority Study and Company, ImClone, Genentech. R. Govindan: F. Honoraria; Covidien, Of Pemetrexed (Pem)+Carboplatin (Cb)+Bevacizumab Pfizer, Astra-Zeneca, GSK, Boehringer-Ingelheim, BMS, Genentech. G. (B) Followed By Maintenance Pem+B Versus Paclitaxel Consultant; Covidien, BMS, Pfizer, GSK, Boehringer-Ingelheim, Astra- (Pac)+Cb+B Followed By Maintenance B In Patients (pts) Zeneca, Genentech. With Stage IIIB Or IV Non-squamous Non-small Cell Lung Cancer (NS-NSCLC) 1 2 3 4 5 J. Patel , M. A. Socinski , E. B. Garon , C. H. Reynolds , D. R. Spigel , R. LBPL2 6 7 7 8 9 1 C. Hermann , J. Liu , S. C. Guba , P. Bonomi , R. Govindan , Northwestern Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial University, Chicago, IL, University of Pittsburgh Medical Center Cancer of Bavituximab Plus Docetaxel in Patients with Previously Pavilion, Pittsburgh, PA, University of California http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

LATE-BREAKING ABSTRACTS

Journal of Thoracic Oncology , Volume 7 – Sep 1, 2012

Loading next page...
 
/lp/wolters-kluwer-health/late-breaking-abstracts-0Sn1vSdKIL
ISSN
1556-0864

Abstract

Company, Genentech. G. Consultant; Eli Lilly and Company, Genentech. LATE-BREAKING PLENARY D.R. Spigel: None. R.C. Hermann: B. Independent Contractor; Eli Lilly and Company. J. Liu: A. Employee; Eli Lilly and Company. K. Stock; Eli Lilly and Company. S.C. Guba: A. Employee; Eli Lilly and Company. K. LBPL1 Stock; Eli Lilly and Company. P. Bonomi: E. Research Grant; Eli Lilly A Randomized, Open-label, Phase 3, Superiority Study and Company, ImClone, Genentech. R. Govindan: F. Honoraria; Covidien, Of Pemetrexed (Pem)+Carboplatin (Cb)+Bevacizumab Pfizer, Astra-Zeneca, GSK, Boehringer-Ingelheim, BMS, Genentech. G. (B) Followed By Maintenance Pem+B Versus Paclitaxel Consultant; Covidien, BMS, Pfizer, GSK, Boehringer-Ingelheim, Astra- (Pac)+Cb+B Followed By Maintenance B In Patients (pts) Zeneca, Genentech. With Stage IIIB Or IV Non-squamous Non-small Cell Lung Cancer (NS-NSCLC) 1 2 3 4 5 J. Patel , M. A. Socinski , E. B. Garon , C. H. Reynolds , D. R. Spigel , R. LBPL2 6 7 7 8 9 1 C. Hermann , J. Liu , S. C. Guba , P. Bonomi , R. Govindan , Northwestern Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial University, Chicago, IL, University of Pittsburgh Medical Center Cancer of Bavituximab Plus Docetaxel in Patients with Previously Pavilion, Pittsburgh, PA, University of California

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2012

There are no references for this article.